RxDoctor Payments Data

Sangeeta Gulati, MD

Gastroenterology · Knoxville, TNNPI 1255418315

Payments from drug & device makers

$8,353in general payments, 2019–2025

Across 455 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$539
  • Gilead$464
  • Bristol Myers Squibb$384
  • Pfizer$363
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,25499%
  • Education$571%
  • Gifts$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,353 in reported general payments places this provider in the 70th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,753
Medicare patients
366
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase28$151,147
LinzessLinaclotide60$81,524
XifaxanRifaximin26$77,546
Mesalamine37$22,911
Dexlansoprazole DrDexlansoprazole32$11,930
ErythromycinErythromycin Base21$6,186
Omeprazole362$5,410
Famotidine331$4,136
Colestipol Hcl20$4,097
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,463
Pantoprazole Sodium221$2,803
Sucralfate20$2,803
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl174$2,778
Dicyclomine Hcl68$2,145
Colesevelam Hcl28$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,876$232,67288 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$333$77,54626 claims
Braintree Laboratories, Inc.Sutab$43$3,46322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →